{"product_id":"global-gene-therapy-partnering-terms-and-agreements-2010-to-2023","title":"Global Gene Therapy Partnering Terms and Agreements 2010 to 2023","description":"\u003cp\u003eGlobal Gene Therapy Partnering Terms and Agreements 2010 to 2023\u003cbr\u003e\nThe Global Gene Therapy Partnering Agreements 2010-2023 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eTrends in gene therapy partnering deals\u003cbr\u003e\nDisclosed headlines, upfronts, milestones and royalties by stage of development\u003cbr\u003e\nGene therapy partnering contract documents\u003cbr\u003e\nTop gene therapy deals by value\u003c\/p\u003e\n\n\u003cp\u003eThe Global Gene Therapy Partnering Terms and Agreements 2010-2023 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R\u0026amp;D, and commercialization of outcomes.\u003c\/p\u003e\n\n\u003cp\u003eThis report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 750 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003c\/p\u003e\n\n\u003cp\u003eContract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.\u003c\/p\u003e\n\n\u003cp\u003eFor example, analyzing actual company deals and agreements allows assessment of the following:\u003c\/p\u003e\n\n\u003cp\u003eWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in gene therapy dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides a review of the leading gene therapy deals since 2010. Deals are listed by headline value, signed by big pharma, most active gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a comprehensive listing of the top 25 most active companies in gene therapy dealmaking with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2010. The chapter is organized by specific gene therapy technology type in focus.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, a comprehensive appendix is provided organized by gene therapy partnering company A-Z, deal type definitions and gene therapy partnering agreements example.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2010.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gene therapy technologies and products.\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Gene Therapy Partnering Terms and Agreements includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in gene therapy dealmaking in the biopharma industry since 2010\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nAccess to over 750 gene therapy deals\u003cbr\u003e\nThe leading gene therapy deals by value since 2010\u003cbr\u003e\nMost active gene therapy dealmakers since 2010\u003cbr\u003e\nThe leading gene therapy partnering resources\u003c\/p\u003e\n\n\u003cp\u003eIn Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:\u003c\/p\u003e\n\n\u003cp\u003eCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nDeal component type\u003cbr\u003e\nSpecific therapy and technology target\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 550 Pages \/ MCW16230277","offer_id":47647063048498,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-gene-therapy-partnering-terms-and-agreements-2010-to-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}